Treatment options in knee osteoarthritis - The patient's perspective

被引:109
作者
Fraenkel, L
Bogardus, ST
Concato, J
Wittink, DR
机构
[1] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA
[2] Yale Univ, Dept Med, New Haven, CT 06520 USA
[3] Yale Univ, Sch Management, New Haven, CT 06520 USA
关键词
D O I
10.1001/archinte.164.12.1299
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The objectives of this study were to (1) examine patient treatment preferences for knee osteoarthritis, (2) determine the influence of specific medication characteristics on patients' choices, and (3) examine whether patient preferences are consistent with current practice. Methods: A total of 100 consecutive patients with symptomatic knee osteoarthritis completed an interactive computer questionnaire administered during a face-to-face interview. We measured the relative impact of specific medication characteristics (including administration, risks, benefits, and cost) on patients' choice, and the percentage of patients preferring nonselective nonsteroidal antiinflammatory drugs (NSAIDs), cyclooxygenase-2 inhibitors, glucosamine and/or chondroitin sulfate, opioid derivatives, and capsaicin across varying risks, benefits, and costs. Results: Of the characteristics studied, variation in the risk of common adverse effects and gastrointestinal ulcer had the greatest impact on patients' choice. Assuming patients are responsible for the full cost of their medications, over 40% prefer capsaicin. Cyclooxygenase-2 inhibitors become patients' preferred choice only if they are described as being 3 times as effective as capsaicin and are covered by insurance. Nonselective NSAIDs are among the least preferred options across all simulations. Conclusions: When evaluating multiple alternatives, many older patients with knee osteoarthritis are willing to forgo treatment effectiveness for a lower risk of adverse effects. The patient treatment preferences derived in this study conflict with the current widespread use of nonselective NSAIDs in older patients with arthritis.
引用
收藏
页码:1299 / 1304
页数:6
相关论文
共 31 条
  • [1] Cannon GW, 2000, ARTHRITIS RHEUM-US, V43, P978, DOI 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO
  • [2] 2-0
  • [3] DEAL CL, 1991, CLIN THER, V13, P383
  • [4] Ehrich EW, 1999, J RHEUMATOL, V26, P2438
  • [5] Unwillingness of rheumatoid arthritis patients to risk adverse effects
    Fraenkel, L
    Bogardus, S
    Concato, J
    Felson, D
    [J]. RHEUMATOLOGY, 2002, 41 (03) : 253 - 261
  • [6] Understanding patient preferences for the treatment of lupus nephritis with Adaptive Conjoint Analysis
    Fraenkel, L
    Bogardus, S
    Wittink, DR
    [J]. MEDICAL CARE, 2001, 39 (11) : 1203 - 1216
  • [7] CONJOINT-ANALYSIS IN MARKETING - NEW DEVELOPMENTS WITH IMPLICATIONS FOR RESEARCH AND PRACTICE
    GREEN, PE
    SRINIVASAN, V
    [J]. JOURNAL OF MARKETING, 1990, 54 (04) : 3 - 19
  • [8] Holt W S Jr, 1992, Fam Med, V24, P524
  • [9] Houpt JB, 1999, J RHEUMATOL, V26, P2423
  • [10] JOHNSON RM, 1987, P SAWT SOFTW C PERC, P253